Wildcat Capital Management’s Allogene Therapeutics ALLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.12M | Hold |
2,920,787
| – | – | 1.85% | 5 |
|
|
2025
Q1 | $4.26M | Hold |
2,920,787
| – | – | 2.28% | 5 |
|
|
2024
Q4 | $6.22M | Hold |
2,920,787
| – | – | 2.46% | 3 |
|
|
2024
Q3 | $8.18M | Hold |
2,920,787
| – | – | 4% | 3 |
|
|
2024
Q2 | $6.81M | Buy |
2,920,787
+1,000,000
| +52% | +$2.33M | 1.67% | 13 |
|
|
2024
Q1 | $7.88M | Hold |
1,920,787
| – | – | 2.86% | 9 |
|
|
2023
Q4 | $6.17M | Hold |
1,920,787
| – | – | 2.13% | 12 |
|
|
2023
Q3 | $6.09M | Hold |
1,920,787
| – | – | 2.45% | 12 |
|
|
2023
Q2 | $9.55M | Hold |
1,920,787
| – | – | 3.63% | 11 |
|
|
2023
Q1 | $9.49M | Sell |
1,920,787
-207,583
| -10% | -$1.03M | 3.53% | 11 |
|
|
2022
Q4 | $13.4M | Hold |
2,128,370
| – | – | 5.11% | 7 |
|
|
2022
Q3 | $23M | Hold |
2,128,370
| – | – | 8.83% | 3 |
|
|
2022
Q2 | $24.3M | Hold |
2,128,370
| – | – | 8.04% | 4 |
|
|
2022
Q1 | $19.4M | Buy |
2,128,370
+412,000
| +24% | +$3.75M | 4.96% | 10 |
|
|
2021
Q4 | $25.6M | Hold |
1,716,370
| – | – | 4.17% | 9 |
|
|
2021
Q3 | $44.1M | Hold |
1,716,370
| – | – | 5.71% | 5 |
|
|
2021
Q2 | $44.8M | Buy |
1,716,370
+200,846
| +13% | +$5.24M | 5.08% | 4 |
|
|
2021
Q1 | $53.5M | Hold |
1,515,524
| – | – | 6.53% | 3 |
|
|
2020
Q4 | $38.3M | Hold |
1,515,524
| – | – | 4.81% | 4 |
|
|
2020
Q3 | $57.2M | Hold |
1,515,524
| – | – | 18.27% | 2 |
|
|
2020
Q2 | $64.9M | Buy |
1,515,524
+165,882
| +12% | +$7.1M | 22.42% | 1 |
|
|
2020
Q1 | $26.2M | Buy |
1,349,642
+147,816
| +12% | +$2.87M | 11.95% | 3 |
|
|
2019
Q4 | $31.2M | Buy |
1,201,826
+295,632
| +33% | +$7.68M | 9.01% | 4 |
|
|
2019
Q3 | $24.7M | Buy |
906,194
+374,028
| +70% | +$10.2M | 10.49% | 3 |
|
|
2019
Q2 | $14.3M | Buy |
+532,166
| New | +$14.3M | 6.18% | 5 |
|